Century Therapeutics Inc. Common Stock
IPSCUnited States
5 filed reports · 241 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 802 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 557 | Dec 2025 |
Financial data
241 concepts · 1,359 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial231 concepts · 1,271 facts · Mar 2024 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Mar 2024 to Jun 2026
- Net income loss12 · Mar 2024 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period before tax12 · Mar 2024 to Jun 2026
- Stockholders equity (US GAAP)12 · Mar 2024 to Jun 2026
- Allocated share based compensation expense11 · Jun 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents11 · Jun 2024 to Jun 2026
- Comprehensive income net of tax11 · Jun 2024 to Jun 2026
- Depreciation11 · Jun 2024 to Jun 2026
- General and administrative expense (US GAAP)11 · Jun 2024 to Jun 2026
- Income tax reconciliation tax credits research11 · Jun 2024 to Jun 2026
- Interest income other11 · Jun 2024 to Jun 2026
- Lease cost11 · Jun 2024 to Jun 2026
- Nonoperating income expense11 · Jun 2024 to Jun 2026
- Operating expenses (US GAAP)11 · Jun 2024 to Jun 2026
- Operating income loss11 · Jun 2024 to Jun 2026
- Operating lease cost11 · Jun 2024 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment before tax11 · Jun 2024 to Jun 2026
- Other nonoperating income expense11 · Jun 2024 to Jun 2026
- Research and development expense excluding acquired in process cost11 · Jun 2024 to Jun 2026
- Variable lease cost11 · Jun 2024 to Jun 2026
- Accretion amortization of discounts and premiums investments10 · Sep 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect10 · Sep 2024 to Jun 2026
- Increase decrease in accounts payable10 · Sep 2024 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities10 · Sep 2024 to Jun 2026
Segment10 concepts · 88 facts · Jun 2024 to Jun 2026
- Facility and other allocated costs11 · Jun 2024 to Jun 2026
- General and administrative expense (US GAAP)11 · Jun 2024 to Jun 2026
- Labor and related expense11 · Jun 2024 to Jun 2026
- Net income loss11 · Jun 2024 to Jun 2026
- Other research and development expense11 · Jun 2024 to Jun 2026
- Research and laboratory11 · Jun 2024 to Jun 2026
- Segment reporting other item amount11 · Jun 2024 to Jun 2026
- Revenue9 · Jun 2024 to Dec 2025
- Asset impairment charges1 · Sep 2025
- Gain loss on termination of lease1 · Jun 2026
Segments
88 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 88 facts
- Single Reportable88 · Jun 2024 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.